Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial - Marconi, VC; Ramanan, AV; de Bono, S (Lancet Respir Med, 2021)